全文获取类型
收费全文 | 784篇 |
免费 | 37篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 45篇 |
妇产科学 | 18篇 |
基础医学 | 94篇 |
口腔科学 | 116篇 |
临床医学 | 98篇 |
内科学 | 128篇 |
皮肤病学 | 3篇 |
神经病学 | 39篇 |
特种医学 | 107篇 |
外科学 | 54篇 |
综合类 | 4篇 |
预防医学 | 25篇 |
眼科学 | 3篇 |
药学 | 24篇 |
肿瘤学 | 65篇 |
出版年
2021年 | 16篇 |
2020年 | 10篇 |
2019年 | 12篇 |
2018年 | 18篇 |
2017年 | 14篇 |
2016年 | 7篇 |
2015年 | 13篇 |
2014年 | 17篇 |
2013年 | 34篇 |
2012年 | 36篇 |
2011年 | 38篇 |
2010年 | 18篇 |
2009年 | 17篇 |
2008年 | 25篇 |
2007年 | 29篇 |
2006年 | 26篇 |
2005年 | 32篇 |
2004年 | 26篇 |
2003年 | 27篇 |
2002年 | 14篇 |
2001年 | 13篇 |
2000年 | 13篇 |
1999年 | 14篇 |
1998年 | 16篇 |
1997年 | 8篇 |
1996年 | 11篇 |
1995年 | 7篇 |
1994年 | 19篇 |
1993年 | 18篇 |
1992年 | 15篇 |
1991年 | 16篇 |
1990年 | 8篇 |
1989年 | 20篇 |
1988年 | 27篇 |
1987年 | 29篇 |
1986年 | 18篇 |
1985年 | 22篇 |
1984年 | 9篇 |
1983年 | 10篇 |
1982年 | 7篇 |
1981年 | 13篇 |
1980年 | 6篇 |
1979年 | 6篇 |
1977年 | 5篇 |
1976年 | 4篇 |
1975年 | 12篇 |
1966年 | 3篇 |
1939年 | 3篇 |
1938年 | 5篇 |
1937年 | 8篇 |
排序方式: 共有828条查询结果,搜索用时 187 毫秒
1.
2.
J N Munck 《Journal of clinical oncology》2003,21(8):1648; author reply 1648-1648; author reply 1649
3.
4.
Occurrence of the t(2;5)(p23;q35) in non-Hodgkin's lymphoma 总被引:9,自引:3,他引:6
Weisenburger DD; Gordon BG; Vose JM; Bast MA; Chan WC; Greiner TC; Anderson JR; Sanger WG 《Blood》1996,87(9):3860-3868
Primary CD30(Ki-1)-positive anaplastic large-cell lymphoma (ALCL) is considered by some to be a distinct clinicopathologic entity associated with the t(2;5) (p23;q35). However, the specificity of t(2;5) for ALCL has not been carefully studied. Therefore, we performed a detailed analysis of all cases of ALCL with abnormal cytogenetics results in the Nebraska Lymphoma Study Group registry, as well as all other cases of non-Hodgkin's lymphoma with t(2;5) in the registry. We found the t(2;5) in only five of 10 cases of ALCL, four of whom were young patients. However, we also found the t(2;5) in 11 other cases of nonanaplastic lymphoma, including eight children with typical peripheral T-cell lymphomas of various types. The t(2;5) was also found in three older adults with B-cell lymphomas of various types. Thus, the t(2;5) was not specific for CD30+ ALCL. However, t(2;5) may define a clinicopathologic entity in children and young adults characterized by variable morphologies with a T-cell or indeterminate phenotype, CD30-positivity, nodal disease with frequent extranodal involvement, advanced stage, and an excellent response to therapy, including bone marrow transplantation for relapsed disease. The clinical relevance of the t(2;5) in older patients requires further study. 相似文献
5.
6.
Braffman BH; Coleman BG; Ramchandani P; Arger PH; Nodine CF; Dinsmore BJ; Louie A; Betsch SE 《Radiology》1994,190(3):797
7.
8.
9.
C von Kalle J Wolf A Becker A Sckaer M Munck A Engert U Kapp C Fonatsch D Komitowski W Feaux de Lacroix 《International journal of cancer. Journal international du cancer》1992,52(6):887-891
No animal model exists for the in vivo growth of Hodgkin's-lymphoma-derived cells. Neither unmanipulated Hodgkin's-disease(HD)-derived cell lines nor primary biopsy tissue could be grown in nude mice. Since the severe combined immunodeficient (SCID) mouse has been reported to be a better recipient for transplanted human lymphatic tissue than the nude mouse, we tested whether SCID mice provide suitable conditions for the in vivo growth of HD cell lines. Tumorigenicity of HD cells was tested in untreated and pre-treated SCID mice and in another combined immunodeficient mouse strain, beige/nude/X-linked immunodeficient (BNX) mouse. SCID mice supported in vivo growth of the 6 HD cell lines tested (L428, L540, L591, DEV, HD-LM2, KM-H2). Only one of the 6 lines (DEV) was tumorigenic in BNX mice. No HD cell line proliferated in T-cell-deficient nude mice. Thus, in vivo growth of HD cell lines appeared to be related to the degree of host immunodeficiency. Additional growth supportive treatments such as fibrosarcoma co-transplantation, intraperitoneal mineral oil injection or immunosuppressive pre-treatment (anti-asialo-GMI-antibody injection) permitted growth of 3 additional HD cell lines in BNX mice. The immunophenotype and karyotype of explanted graft cells were identical to the original cell lines. Our experiments describe an effective and reproducible xenograft model for growth of Hodgkin's-disease-derived cell lines. This may be of value for elucidating the growth characteristics of Hodgkin's-lymphoma-derived cells as well as for testing new therapeutic regimens. 相似文献
10.
Luis H. Ramirez Morbize Juliéron Marc Bonnay Serge Koscielny Zhongxin Zhao Alain Gouyette Jean-Nicolas Munck 《Investigational new drugs》1995,13(1):51-53
Suramin is an antitrypanosomal compound with confirmed efficacy against several human malignancies. It is generally assumed
that its mechanism of action includes the interaction with different growth factors, unlike most of the anticancer drugs.
Its anticancer activity has not been testedin vivo against squamous cell carcinoma. The purpose of this study was to assess the efficacy and toxicity of suraminin vivo andin vitro on the VX2 tumor model at therapeutic monitored plasma concentrations. We determined the pharmacokinetics of suramin in rabbits,
and modelized its administration in order to obtain plasma concentrations between 150 and 300 μg/ml throughout the treatment
course of 3 weeks. Under these conditions, antitumor effects of suramin were evaluatedin vivo by comparing liver tumor involvement in suramin-treated and control rabbits. Liver involvement was quantified by image analysis
andin vitro effects were also determined at the same concentrations.In vivo, suramin promoted liver tumor growth significantly (p<0.05), compared to untreated controls.In vitro, suramin significantly stimulated tumor cell growth at concentrations above 200 μg/ml (p<0.01). Suramin may have stimulatory
effects on tumor growth in squamous cell carcinoma at relevant plasma drug concentrations. Caution should be taken in further
trials in patients with squamous cell carcinomas. 相似文献